NCT03048695

Brief Summary

About 85% of patients with schizophrenia have cognitive impairments, executive functions being particularly affected. Executive dysfunction, and cognitive deficits in general, are important predictors of functional outcomes, including social problem solving, activities of daily living, life satisfaction, and the ability to return to work or school.The main objective of the current study is to examine the efficacy of group-based Goal Management Training (GMT) for patients with broad schizophrenia spectrum disorders or high risk individuals with executive deficits. The short term goals are to investigate whether GMT can improve participants' ability to organize and achieve goals in everyday life in addition to improving aspects of emotional health. A long-term goal would be to establish an evidence base for nonpharmacological interventions for patients with broad schizophrenia spectrum disorders or high risk for schizophrenia. Main research questions: (1) Does a RCT with GMT delivered to patients with broad schizophrenia spectrum disorders or high risk for schizophrenia result in improved executive functioning, measured by self-reported and/or objective measures of executive functions? (2) Does GMT result in improved goal attainment in everyday life, social- and real world functioning? (3) Does GMT have a positive impact on the patients' emotional health? (4) Are there specific characteristics in patients with broad schizophrenia spectrum disorders or high risk for schizophrenia that are associated with better treatment benefit from GMT?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
83

participants targeted

Target at P50-P75 for not_applicable schizophrenia

Timeline
Completed

Started May 2017

Typical duration for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2017

Completed
24 days until next milestone

First Posted

Study publicly available on registry

February 9, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

May 18, 2017

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

February 10, 2021

Status Verified

February 1, 2021

Enrollment Period

3.6 years

First QC Date

January 16, 2017

Last Update Submit

February 9, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • Behavior Rating Inventory for Executive Functions

    Assessing change

    Baseline, immediately post-intervention and 6 months follow-up

  • Conners Continuous Performance Test III

    Assessing change

    Baseline, immediately post-intervention and 6 months follow-up

  • Positive and Negative Syndrome Scale

    Assessing change

    Baseline, immediately post-intervention and 6 months follow-up

Secondary Outcomes (14)

  • Global Assessment of Functioning-Split Version

    Baseline, immediately post-intervention and 6 months follow-up

  • The Hotel Task

    Baseline, immediately post-intervention and 6 months follow-up

  • Delis Kaplan Executive Function System (D-KEFS) subtests

    Baseline, immediately post-intervention and 6 months follow-up

  • Digit span and Letter-number sequencing

    Baseline, immediately post-intervention and 6 months follow-up

  • Iowa Gambling Task

    Baseline, immediately post-intervention and 6 months follow-up

  • +9 more secondary outcomes

Study Arms (2)

Goal Management Training

EXPERIMENTAL

Cognitive rehabilitation

Behavioral: GMT

Waiting list

NO INTERVENTION

Interventions

GMTBEHAVIORAL

Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance

Goal Management Training

Eligibility Criteria

Age16 Years - 67 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Being consecutively referred to treatment for a DSM-IV diagnosis of broad schizophrenia spectrum psychosis (schizophrenia, schizophreniform disorder and schizoaffective disorder) or high risk for psychosis or being treated for psychotic disorder for less than 5 years.
  • Reporting executive problems through (a) structured interview, or (b) self-report, i.e. BRIEF scale T-score \< 55.

You may not qualify if:

  • Reported ongoing alcohol or substance abuse.
  • Premorbid neurological disease or insult and/or comorbid neurological disease. ° Severe cognitive problems interfering with the capacity to participate.
  • IQ below 70.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sykehuset Innlandet Reinsvoll

Reinsvoll, 2840, Norway

Location

Related Publications (3)

  • Orm S, Oie MG, Haugen I. Iowa Gambling Task performance in individuals with schizophrenia: the role of general versus specific cognitive abilities. Front Psychiatry. 2024 Dec 10;15:1454276. doi: 10.3389/fpsyt.2024.1454276. eCollection 2024.

  • Oie MB, Haugen I, Stubberud J, Oie MG. Effects of Goal Management Training on self-efficacy, self-esteem, and quality of life for persons with schizophrenia spectrum disorders. Front Psychol. 2024 Mar 7;15:1320986. doi: 10.3389/fpsyg.2024.1320986. eCollection 2024.

  • Haugen I, Stubberud J, Haug E, McGurk SR, Hovik KT, Ueland T, Oie MG. A randomized controlled trial of Goal Management Training for executive functioning in schizophrenia spectrum disorders or psychosis risk syndromes. BMC Psychiatry. 2022 Aug 28;22(1):575. doi: 10.1186/s12888-022-04197-3.

MeSH Terms

Conditions

SchizophreniaNeurocognitive Disorders

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • Merete G Øie, Phd

    Sykehuset Innlandet HF

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 16, 2017

First Posted

February 9, 2017

Study Start

May 18, 2017

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

February 10, 2021

Record last verified: 2021-02

Locations